A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (Q34459729)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

corrigendum / erratum

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

0 references

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Anne-Marie Landtblom

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Miguel Angel Macias-Islas

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Ovidiu A Bajenaru

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Adriana Carrá

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Nina de Klippel

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

João C de Sá

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Astrid Edland

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Jette L Frederiksen

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Olivier Heinzlef

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Klimentini E Karageorgiou

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Rafael H Lander Delgado

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Niall Tubridy

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Yossi Gilgun-Sherki

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Journal of Neurology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

261

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

2101-2111

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

copyright license

Creative Commons Attribution 4.0 International

14 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s00415-014-7446-0

0 references

Thalamo-striato-cortical determinants to fatigue in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Switching therapies in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Multiple sclerosis: pathogenesis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Multiple sclerosis beyond EDSS: depression and fatigue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Maximising therapeutic outcomes in patients failing on current therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Switching algorithms: from one immunomodulatory agent to another

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Origin of fatigue in multiple sclerosis: review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Risk-benefit assessment of glatiramer acetate in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Validation of the functional assessment of multiple sclerosis quality of life instrument

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Paced auditory serial-addition task: a measure of recovery from concussion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221652

6 July 2018

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

A method for evaluating treatment switching criteria in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Glatiramer acetate: mechanisms of action in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Voxelwise Assessment of the Regional Distribution of Damage in the Brains of Patients with Multiple Sclerosis and Fatigue

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7446-0

21 January 2018

Clinically significant liver injury in patients treated with natalizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25119836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Visual function and subjective quality of life compared in subjects with acquired macular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25119836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25119836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25119836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression to the mean in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25119836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing depressive symptoms in five psychiatric populations: a validation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25119836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-014-7446-0

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119836%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34459729&oldid=1860802788"